OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Neurology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Multidisciplinary care for amyotrophic lateral sclerosis	1132
Correction to Lancet Neurol 2021; 20: 448–59	959
Correction to Lancet Neurol 2024; 23: 168–77	875
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	743
Traumatic brain injury research: homogenising heterogeneity	715
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	652
Increasing diversity in dementia research	545
The predictive value and clinical use of the neurological pupillary index – Authors' reply	498
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	496
Lessons and future directions for GBA1-targeting therapies	478
Correction to Lancet Neurol 2022; 21: 42–52	466
Implications of the KIWE trial for low-income and lower-middle-income countries	440
Correction to Lancet Neurol 2020; 19: 391–401	397
Correction to Lancet Neurol 2025; 24: 850–65	396
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	363
The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease	350
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	349
Dementia diagnosis in the anti-amyloid era	307
Global burden of stroke: dynamic estimates to inform action	292
Anti-CD19 CAR T cells for refractory myasthenia gravis	267
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	253
RAB32 mutation in Parkinson's disease	250
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	247
The relevance of social and commercial determinants for neurological health	242
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	228

Management of atherosclerotic extracranial carotid artery stenosis	225
A biological classification of Huntington's disease: the Integrated Staging System	208
Surrogate endpoints for progressive multifocal leukoencephalopathy	202
The prescription of valproate: risk of harm	196
Diana Cejas	193
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	191
Considering the neurological health needs of LGBTQIA people	190
Elia M Pestana Knight	187
Aspiring to restore arm and hand function after stroke	183
Beyond the modular brain	183
Albert Kwaku Akpalu	168
A sensitive portrayal of a controversial condition	166
A chilly tale of dementia	163
A nasal CGRP receptor antagonist for acute migraine therapy	162
A study in healing the wounds of trauma	160
Trials in intracerebral haemorrhage: a path to success?	157
Delving into the human mind	155
Correction to Lancet Neurol 2023; 22: 812–25	155
Correction to Lancet Neurol 2022; 21: 284–94	154
From stroke awareness to stroke action awareness	153
Amyotrophic lateral sclerosis from genotoxins alone?	140
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment	138
Epilepsy syndromes: an essential piece of the puzzle	136
Development of treatments for Down syndrome	127
Gene therapy for X-linked myotubular myopathy: the challenges	124
Global burden of headache disorders: innovations, disparities, and priorities for action	124
2025 for neuromuscular diseases: a year of multiple advances	123
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	123
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	122
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	120
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	120
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	119
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	117
Parkinson's disease is a recognisable and useful diagnostic entity	115
Movement disorders research in 2021: cracking the paradigm	114
Functional or hysterical?	113
Cognitive function in people with functional seizures	111
A proposal for equity neuroscience	110
Rethinking AI trials in brain health	108
Changing multiple-sclerosis-induced thoughts and behaviours	107
Supporting young carers across neurological disorders	106
Learning to be an adult with a disability	104
Revisiting candesartan: new evidence for an old option in migraine prevention	103
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	103
Multiple sclerosis in 2022: old players, new insights	102
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	100
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial	99
New results for risdiplam in spinal muscular atrophy	98
Responsible innovation in neurology	93
Expansion of stenting indications in the USA	93

Correction to Lancet Neurol 2024; 23: 110–22	93
Correction to Lancet Neurol 2022; 21: 620–31	92
Jessica Ailani	92
Neurological infections in 2023: surveillance and prevention	91
Encephalitis awareness: our ambitious global endeavour	91
Brain health in the Philippines	91
Major advances in Parkinson's disease over the past two decades and future research directions	89
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	87
Detection of ionising radiation by the CNS: a case report	87
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	86
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	86
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	85
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	83
Exploring immunomodulation with azathioprine in Parkinson's disease	83
Spontaneous intracranial hypotension: searching for the CSF leak	82
α-synuclein seed amplification and its uses in Parkinson's disease	81
Detection of awareness after brain injury: time for change	80
Improving thrombolysis efficiency for acute ischaemic stroke	78
ELEVATEd hope for patients after migraine treatment failure	78
Pragmatic solutions for the global burden of stroke	77
Highlights in traumatic brain injury research in 2024	76
A call for optimal oral care in patients with ALS	76
Correction to Lancet Neurol 2024; 23: 961–62	73
Andrea Schneider	73
Monitoring brainwaves while gallery visitors view artworks	73
Expanding the spectrum of type 1 IFN neuroinflammation	72
Neuroprotection in acute ischaemic stroke: reasons for optimism?	72
Eugenia Martínez	71
Blocking inhibitors of axon growth after spinal cord injury	70
Brains are neither pink nor blue but fifty shades of grey matter	70
Your After-Visit Summary—May 29, 2042	70
Sleeping matters	67
Bastiaan Bloem: power against Parkinson's disease	66
Headache research in 2023: advancing therapy and technology	65
Consciousness contextualised	64
Epilepsy research in 2022: clinical advances	62
The global challenge of hypertension	61
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	61
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	60
Living with dementia: seeing the world and adapting to it	60
Neurorehabilitation as a cornerstone of recovery	59
Targeting auto-antibodies for CIDP: hope and questions	59
Correction to Lancet Neurol 2024; 23: 344–81	59
Siddharth Srivastava	58
Caution on the use of α2δ-ligands in neuropathic pain	57
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	56
Thrombolysis before endovascular treatment of tandem lesions	56
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	56
The AfrAbia+plus Parkinson's Disease Genomic Consortium	55
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	55
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	55
Diagnosis and treatment of orthostatic hypotension	55
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	54
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	53
The torment of needing to know for sure	53
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	53
Changing the landscape of neurological education	52
Angela Dos Santos	52
Correction to Lancet Neurol 2024; 23: 465–76	52
Charles Bell's Renaissance inspiration	51
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	51
NfL is ready for translation into paediatrics	50
Essential medicines for neurological disorders: updates, rejections, and the road ahead	50
Advances in amyotrophic lateral sclerosis research in 2022	49
Over a decade of MR-guided focused ultrasound	48
No area of stroke research should be left behind	48
Therapies for myasthenia gravis: FcRn inhibition and beyond	48
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	48
Geoffrey Manley: TBI guy	47
The bases of remembrance	47
The cultural history of dementia	46
Major advances in sleep neurology: 2002–22	46
Neurosurgical lesioning for Tourette syndrome – Authors' reply	46
Early atrial fibrillation rhythm control after stroke	46
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	45
Carlayne Jackson: leading the American Academy of Neurology	45
A brain design for life	44
Further support for rituximab in relapsing multiple sclerosis	44
Charles Sherrington's apparatus	43
Laquinimod, Huntington's disease, and disease modification	42

Sleep research in 2023: beyond the bare necessities	42
Biomedical research must change as the climate does	42
Digital mobility measures to predict Parkinson's disease	42
For a dementia diagnosis, clinical acumen must precede biomarkers	41
Correction to Lancet Neurol 2021; 20: 1012–16	41
Thank you to The Lancet Neurology's peer reviewers in 2023	40
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	40
A decisive year for the neurological community	39
Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	39
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	39
The complex pathway between amyloid β and cognition: implications for therapy	38
Diagnostic and other biomarkers of dementia with Lewy bodies: from research to clinical settings	38
Frailty and outcome after traumatic brain injury	37
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	37
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	36
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	36
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	34
Nanna Brix Finnerup: integrity and openness to alternatives	34
Improving epilepsy diagnosis across the lifespan: approaches and innovations	34
Video games for people with neurological disorders	33
Acute-onset axonal neuropathy following infection in children with biallelic RCC1 variants: a case series	33
Maria Trojano: advocate for real-world multiple sclerosis studies	33
Correction to Lancet Neurol 2025; 24: 413–28	32
Correction to Lancet Neurol 2024; 23: 344–81	31
The prescription of valproate: risk of harm	31
Neuroscience in the 21st century: circuits, computation, and behaviour	30
Global burden of meningitis and implications for strategy	30
Neuroscience research in 2024: advances in blood biomarkers and brain omics	30
Helping to bring the crisis home	30
Correction to Lancet Neurol 2021; 20: 615–26	30
Teshamae Monteith	29
Sleep matters in anti-LGI1 encephalitis	29
Correction to Lancet Neurol 2025; 24: 880–92	29
Correction to Lancet Neurol 2023; 22: 209–17	29
Nitrous oxide and its neurological harms	29
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	29
Blue as an orange	29
Friston's theory of everything	29
Revisiting levodopa for advanced Parkinson's disease	29
Globally advancing neurological education in headache	29
Brain amyloid on the way to dementia prevention	28
RAB32 mutation in Parkinson's disease	28
Correction to Lancet Neurol 2025; 24: 969–75	28
Abandon the NAC in α-synuclein	28
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	26
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	26
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	26
Advances in diagnosis, classification, and management of pain in Parkinson's disease	26
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	25
Amyotrophic lateral sclerosis: a lesson in translation	25
Time to get serious about the Global Action Plan on dementia	25
Addressing neurological burden in the Americas	25
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	25
Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023	24
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	24
A disease-specific therapy in facioscapulohumeral muscular dystrophy	24
Time to end the stigma of epilepsy	24
A neurotransmitter with a fascinating story	24
Transforming amyotrophic lateral sclerosis into a liveable disease	23
Neuropsychiatry on screen	23
Carotid revascularisation for carotid stenosis	23
CGRP blockade and cluster headache: another step forward	23
William Harvey, neurologist?	22
Lightning progress in child neurology in the past 20 years	22
With thanks to our peer reviewers in 2022	22
Krithi Irmady	22
Dancing with paper	22
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	22
Vittorio Marchi's staining	22
CGRP-targeted drugs for migraine: still many uncertainties	22
Cerebral amyloid angiopathy criteria: the next generation	21
Treatment of asymptomatic carotid stenosis in SPACE-2	21
Fetal exposure to antiseizure medications: reassurance and concerns	20
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	20
Treatment of acute subdural haematoma – Authors' reply	20
Innovation in the prevention of neurological diseases	20
Chronic effects of inflammation on tauopathies	19
Neurology cannot be embedded in non-communicable disease agendas	19
Differential diagnosis of suspected multiple sclerosis: global health considerations	19
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	19
The neuropsychiatry of Parkinson's disease: advances and challenges	19
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	19
The hidden unity of the mind	19
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	18
Elucidating a new path of CSF transport in the CNS	18
Carpal tunnel syndrome: updated evidence and new questions	18
Changing views of disability	18
Dealing with the reproducibility crisis in neuroscience from the grassroots	18
Criteria for a biological definition of neuronal α-synuclein disease—a major conceptual step forward	17
Pragmatic solutions for the global burden of stroke	17
Nosferatu and the cinematic unglory of hysteria	17
Effects of spaceflight on the brain	17
Mar Tintoré, Mar Mediterráneo	17
Natural neuroscience: rethinking brain research beyond the lab	17
Amyloid β, γ-secretase, and familial Alzheimer's disease	17